SCHEMBL3616202

SCHEMBL3616202

COc1ccc(-c2cc[nH]n2)cc1OC1CCCC1

nearest known ligand 0.59

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 16/20 0.59
PDE4B Q07343 12/20 0.54
PDE4C Q08493 12/20 0.54
PDE4D Q08499 12/20 0.54
S1PR1 P21453 1/20 0.50
S1PR3 Q99500 1/20 0.50
FPR2 P25090 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17003768 0.84 PDE4D (0.50) PDE4APDE4BPDE4CPDE4D
SCHEMBL5823060 0.82 PDE4A (0.77) PDE4APDE4BPDE4CPDE4DS1PR1
SCHEMBL2389958 0.82 PDE4A (0.61) PDE4APDE4BPDE4CPDE4D
SCHEMBL8632255 0.82 PDE4A (0.71) PDE4APDE4BPDE4CPDE4D
SCHEMBL8631909 0.81 PDE4A (0.70) PDE4APDE4BPDE4CPDE4D
SCHEMBL3608991 0.81 PDE4B (0.45) PDE4APDE4BPDE4CPDE4DFPR2
SCHEMBL8685742 0.79 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DS1PR1
SCHEMBL18288862 0.79 FPR2 (0.37) PDE4APDE4BPDE4CPDE4DFPR2
SCHEMBL8204793 0.77 PDE4A (0.77) PDE4APDE4BPDE4CPDE4DFPR2
SCHEMBL17010347 0.77 PDE4A (0.60) PDE4APDE4BPDE4CPDE4DFPR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7495017-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION (US) 2009-02-24 US claimed
US-20070203197-A1 Phosphodiesterase 4 inhibitors HOPPER ALLEN 2007-08-30 US claimed
CN-1809559-A Pyrazole derivatives as phosphodiesterase 4 inhibitors MEMORY PHARM CORP (US) 2006-07-26 CN claimed
EP-1631568-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceuticals Corporation (US) 2006-03-08 EP claimed
US-20040229918-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2004-11-18 US claimed
WO-2004094411-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-11-04 WO claimed
EP-3105206-B1 MORPHOLINE DERIVATIVES HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY UNIV DEGLI STUDI GENOVA (IT) 2019-08-07 EP disclosed
US-10017480-B2 Compounds having a selective PDE4D inhibiting activity UNIVERSITA DEGLI STUDI DI GENOVA (IT) 2018-07-10 US disclosed
US-10017480-B2 Compounds having a selective PDE4D inhibiting activity UNIVERSITA DEGLI STUDI DI GENOVA (IT) 2018-07-10 US disclosed
US-10017480-B2 Compounds having a selective PDE4D inhibiting activity UNIVERSITA DEGLI STUDI DI GENOVA (IT) 2018-07-10 US disclosed
EP-3105206-A1 NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY Universita' degli Studi di Genova (IT) 2016-12-21 EP disclosed
US-20160355489-A1 NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY THE TRUSTEES OF COLUMBIA UNIVERSITY 2016-12-08 US disclosed
US-20160355489-A1 NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY THE TRUSTEES OF COLUMBIA UNIVERSITY 2016-12-08 US disclosed
US-20070203197-A1 Phosphodiesterase 4 inhibitors HOPPER ALLEN 2007-08-30 US disclosed
US-7226930-B2 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICAL CORPORATION (US) 2007-06-05 US disclosed
CN-1809559-A Pyrazole derivatives as phosphodiesterase 4 inhibitors MEMORY PHARM CORP (US) 2006-07-26 CN disclosed
US-20060154960-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2006-07-13 US disclosed
EP-1631568-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS Memory Pharmaceuticals Corporation (US) 2006-03-08 EP disclosed
US-20040229918-A1 Phosphodiesterase 4 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2004-11-18 US disclosed
WO-2004094411-A1 PYRAZOLE DERIVATIVES AS PHOSPHODIESTERASE 4 INHIBITORS MEMORY PHARMACEUTICALS CORPORATION (US) 2004-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160355489-A1 NEW COMPOUNDS HAVING A SELECTIVE PDE4D INHIBITING ACTIVITY PDE4A, PDE4D, PDE4B PDE4A 1/4885PDE4B 3/4885PDE4C 5/4885
US-20070203197-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885
US-20060154960-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885
US-20040229918-A1 Phosphodiesterase 4 inhibitors PDE4A, PDE4B, PDE12 PDE4A 1/4885PDE4B 2/4885PDE4C 7/4885
US-10017480-B2 Compounds having a selective PDE4D inhibiting activity PDE4A, PDE4D, PDE2A PDE4A 1/4885PDE4B 4/4885PDE4C 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.